Physician Photo

Keith T. Flaherty, MD

  • Phone: 617-724-4800
Department of Medicine


  • Cancer Center
  • Melanoma
Boston: Massachusetts General Hospital
Medical Education
MD, Johns Hopkins University School of Medicine
Residency, Brigham and Women's Hospital
Fellowship, Hospital of the University of Pennsylvania
Board Certifications
Medical Oncology, American Board of Internal Medicine
Patient Age Group
Accepting New Patients
Accepting New Patients

Dr. Keith Flaherty

Dr. Keith Flaherty is the director of the Henri and Belinda Termeer Center for Targeted Therapies. Dr. Flaherty and his exceptional team of clinicians and scientists are spearheading research into promising new treatment options for patients through phase I clinical investigation.

Three MGH teams honored for clinical research achievements

Three projects led by MGH investigators were named among the Clinical Research Forum’s Top 10 Clinical Research Achievements of 2012 at the organization’s annual meeting on April 18.

Cancer Center physicians honored

The Henri and Belinda Termeer Center for Targeted Therapies in the MGH Cancer Center has three new endowed leadership positions.

Targeted drug leads to rapid regression of metastatic melanoma in patients with mutated BRAF gene

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

Combination of targeted treatment drugs delays resistance in melanoma patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

Three Mass. General researchers among recipients of Top 10 Clinical Research Achievement awards

Three projects led by Massachusetts General Hospital (MGH) investigators have been named among the Clinical Research Forum's Top 10 Clinical Research Achievements of 2012.

55 Fruit Street
Boston, MA 02114-2696

Phone: 617-724-4800